



COVID-19

DIAGNOSIS AND MANAGEMENT

PART II

Editors:

Neeraj Mittal
Sanjay Kumar Bhadada
O. P. Katare
Varun Garg

Bentham Books

COVID-19: Diagnosis and Management-Part II

Edited by

Neeraj Mittal

Department of Endocrinology

Postgraduate Institute of Medical Education and Research

Chandigarh-160012

India

Sanjay Kumar Bhadada

Department of Endocrinology

Postgraduate Institute of Medical Education and Research

Chandigarh-160012

India

O.P. Katare

University Institute of Pharmaceutical Sciences

UGC Centre of Advanced Studies

Punjab University

Chandigarh-160014

India

&

Varun Garg

Department of Medical Affairs

Cadila Healthcare Limited

Ahmedabad 382421

Gujarat

India

COVID-19: Diagnosis and Management-Part II

Editors: Neeraj Mittal, Sanjay Kumar Bhadada, O. P. Katare and Varun Garg

ISBN (Online): 978-1-68108-805-1

ISBN (Print): 978-1-68108-806-8

ISBN (Paperback): 978-1-68108-807-5

© 2021, Bentham Books imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is 1. the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
LIST OF CONTRIBUTORS	iv
CHAPTER 1 PREVENTION OF COVID-19: FACTS TO OVERCOME THE MYTHS	1
<i>Rajesh Kumar, Mangesh Pradeep Kulkarni, Sheetu Wadhwa and Soundappan Kathirvel</i>	
INTRODUCTION	2
MEASURES TO PREVENT THE SPREAD, ASSOCIATED MYTHS AND FACTS	3
Personal Protective Equipment (PPE)	3
<i>Head Covers</i>	4
<i>Face Shield</i>	4
<i>Mask</i>	4
<i>Goggles</i>	6
<i>Gloves</i>	7
<i>Shoe Covers</i>	7
<i>Gowns or Coveralls</i>	7
SANITIZATION AND DISINFECTION	9
Hand Hygiene	9
<i>For Public</i>	10
<i>Prevention of COVID-19 Among Frontline Healthcare Workers</i>	10
Cleaning of Vegetables-Fruits	10
Safe Handling of Currency and Paper Documents	11
Cough or Respiratory Etiquettes	12
<i>Precautions to be Taken While Coughing/Sneezing or Any Physical Contact</i>	12
<i>Spitting or Littering in Public</i>	12
Disinfection of Public Places	12
Disposal and Disinfection of PPEs	13
WATER TREATMENT AND WASTE MANAGEMENT	13
Management of Water and Faecal Waste	13
Safety of Water Supplies	14
SOCIAL MEASURES	14
Physical Distancing	14
Quarantine and Isolation	16
<i>Home Quarantine</i>	16
<i>Institutional Quarantine</i>	17
<i>Staff Guidelines</i>	17
<i>Utility Guidelines</i>	17
Lockdown and Travel Restrictions	18
Zonal Classification of the Geography	19
PROPHYLAXIS FOR COVID-19	19
Dietary Recommendations for the Prevention of COVID-19	19
<i>General Measures</i>	19
<i>Medicinal Plant Measures/Procedures</i>	20
Medical Prophylaxis for Healthcare Workers and Contacts of a Positive Patient	20
REGULAR SCREENING	21
PRECAUTIONS FOR TRAVEL	22
CONCLUSION	22
LIST OF ABBREVIATIONS	23

CONSENT FOR PUBLICATION	24
CONFLICT OF INTEREST	24
ACKNOWLEDGEMENTS	24
REFERENCES	24
CHAPTER 2 CURRENT TREATMENT METHODS FOR CORONAVIRUS DISEASE-19	27
<i>Kuldeep Kumar, Sonal, Pankaj Bhatia, Dhandeep Singh, Amteshwar S. Jaggi and Nirmal Singh</i>	
INTRODUCTION	28
OVERVIEW OF VARIOUS TREATMENT STRATEGIES FOR COVID-19	28
Hydroxychloroquine	28
<i>HCQ in Treatment of COVID-19</i>	29
Remdesivir	31
<i>Remdesivir in Treatment of COVID-19</i>	31
Lopinavir/Ritonavir	32
<i>Lopinavir/Ritonavir in Treatment of COVID-19</i>	32
Favipiravir	33
<i>Favipiravir in Treatment of COVID-19</i>	33
Azithromycin (AZ)	34
<i>AZ in COVID-19 Treatment</i>	34
Arbidol	35
<i>Arbidol in Treatment of COVID-19</i>	36
Ribavirin	36
<i>Ribavirin in COVID-19 Treatment</i>	37
Teicoplanin	37
<i>Teicoplanin in COVID-19 Treatment</i>	37
Ivermectin	38
<i>Ivermectin in Treatment of COVID-19</i>	38
Nitazoxanide	39
<i>Nitazoxanide in COVID-19 Treatment</i>	39
Corticosteroids	39
<i>Corticosteroids in the Treatment of COVID-19</i>	40
Immuno Modulating Agents-Interferons (IFN's)	42
<i>IFN's in Treatment of COVID-19</i>	42
Monoclonal Antibody Therapy	43
80R Immunoglobulin G1 (IgG1)	44
CR3014	45
Monoclonal Antibody Therapy in COVID-19 Treatment	45
Tocilizumab	45
Sarilumab	46
<i>Limitations and Suggestions Regarding mAb's</i>	46
Triple Therapy	46
Miscellaneous Drugs	47
Herbal Drugs for COVID-19	48
Glycyrrhizin	48
<i>Glycyrrhizin in COVID-19</i>	49
Hesperetin	49
Baicalin	49
Scutellarin	49
Plasma Therapy	50
Plasma Therapy in the Treatment of COVID-19	50

Potential of Stem Cell Therapy in COVID-19	51
BCG Vaccine	51
VARIOUS REGULATORY GUIDELINES GIVEN BY NIH (NATIONAL INSTITUTE OF HEALTH) FOR TREATMENT OF COVID-19	52
CONCLUSION	53
LIST OF ABBREVIATIONS	53
AUTHORS CONTRIBUTION	54
CONSENT FOR PUBLICATION	54
CONFLICT OF INTEREST	54
ACKNOWLEDGEMENTS	55
REFERENCES	55
CHAPTER 3 COVID-19 AND MORTALITY	71
<i>Rimesh Pal and Sanjay Kumar Bhadada</i>	
INTRODUCTION	71
REPRESENTING MORTALITY – MORTALITY RATE VS. CASE-FATALITY RATE ...	73
FALLACIES IN ESTIMATING MORTALITY USING CASE-FATALITY RATE	73
REPORTING COVID-19-RELATED DEATHS	74
COMPARING CASE-FATALITY RATES OF COVID-19 WITH OTHER RELATED VIRAL DISEASES	75
COMPARING COVID-19 CASE-FATALITY RATES AMONG VARIOUS NATIONS	76
CAUSES OF DEATH IN COVID-19	77
PARAMETERS PREDICTING MORTALITY IN COVID-19	80
Clinical Parameters	80
<i>Age</i>	<i>80</i>
<i>Gender</i>	<i>81</i>
<i>Symptoms</i>	<i>82</i>
<i>Complications</i>	<i>82</i>
<i>Comorbid Illness</i>	<i>83</i>
<i>Smoking</i>	<i>85</i>
<i>Secondary Infections</i>	<i>85</i>
Laboratory Parameters	86
CONCLUSION	88
ABBREVIATIONS	88
CONSENT FOR PUBLICATION	89
CONFLICT OF INTEREST	89
ACKNOWLEDGEMENTS	89
REFERENCES	89
CHAPTER 4 LONG TERM COMPLICATIONS OF COVID-19	96
<i>Ankita Sood, Bimlesh Kumar Indu Melkani, Archit Sood, Pankaj Prashar, Anamika Gautam Kardam Joshi and Dhara Patel</i>	
INTRODUCTION	96
LONG TERM COMPLICATIONS OF COVID-19	98
COMPLICATIONS OF COVID-19 IN VARIOUS DISEASES	100
Diabetes Mellitus (DM)	100
Hematological Complications	103
Cardiovascular Diseases	107
Central Nervous System Complications	108
<i>Viral Encephalitis</i>	<i>108</i>
<i>Infectious Toxic Encephalopathy and Cerebrovascular Disease</i>	<i>109</i>
Chronic Kidney Disease (CKD)	110

Asthma and Respiratory Disorders	111
Rheumatoid Arthritis (RA)	115
CONCLUSION	116
ABBREVIATIONS	116
CONSENT FOR PUBLICATION	117
CONFLICT OF INTEREST	117
ACKNOWLEDGEMENTS	117
REFERENCES	117
CHAPTER 5 VACCINE DEVELOPMENT	125
<i>Priya Sharma, Shivani Joshi, Aishwarya Joshi, Nikunj Tandel and Rajeev K. Tyagi</i>	
COVID-19: VACCINE DEVELOPMENT	126
COVID-19 VACCINE DEVELOPMENT: MODULATING THE HOST IMMUNE SYSTEM	127
TYPES OF VACCINES AND THEIR CHARACTERISTICS	130
Live-attenuated Virus and Inactivated Whole Virus Vaccines	130
Subunit Vaccines	130
Vaccines Based on Virus-like Particles (VLPs)	132
Viral Vector-based Vaccines	134
DNA Vaccines	135
NOVEL APPROACHES: USAGE OF MULTIDISCIPLINARY FIELDS	137
Serum Albumin Strategy	137
Natural Product (Plant) Based Technology	137
Nanotechnology and Material Science	139
mRNA Based Approaches	139
ANIMAL MODELS TO TEST THE IMMUNOGENIC POTENTIAL OF CANDIDATE VACCINE ANTIGENS	140
Animal Models Currently in Practice	141
Humanized Mice Models	143
Novel Approach of Using Zebrafish (Their Advantages)	144
CURRENT STATUS OF VACCINE DEVELOPMENT	146
BENCH TO BEDSIDE: OBSTACLES AND OUTCOMES	156
Lessons from Previous Vaccine Development	157
LIST OF ABBREVIATIONS	159
CONSENT FOR PUBLICATION	160
CONFLICT OF INTEREST	160
ACKNOWLEDGEMENTS	160
REFERENCES	161
CHAPTER 6 THE FUTURE OF COVID-19 TREATMENT	169
<i>Sahil Arora, Manvendra Kumar, Gaurav Joshi and Raj Kumar</i>	
INTRODUCTION	169
DRUGS AFFECTING VIRAL REPLICATION AND TRANSLATION IN COVID-19 DISEASE	172
DRUGS INTERFERING WITH INFLAMMATION AND OVERCOMING CYTOKINE STORM IN COVID-19 DISEASE	175
ANTICANCER DRUGS IN THE TREATMENT OF COVID-19 DISEASE	179
ANTIPARASITIC, ANTIPROTOZOAL, AND ANTIFUNGAL DRUGS IN THE TREATMENT OF COVID-19 DISEASE	181
DRUGS AFFECTING THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN COVID-19	183

MISCELLANEOUS	185
DISCUSSION AND CONCLUSION	186
ABBREVIATIONS	190
CONSENT FOR PUBLICATION	191
CONFLICT OF INTEREST	191
ACKNOWLEDGEMENTS	191
REFERENCES	191
SUBJECT INDEX	201

FOREWORD

It is my proud privilege to introduce the book “Covid-19: Diagnosis and Management,” which is authored by a group from PGIMER, Chandigarh. The timing of this monograph is very apt as it has been about 9 months since the start of the COVID-19 pandemic, and it is now that we are starting to unravel the various mechanisms of disease pathogenesis and treatment modalities for this viral infection which has infected 29 million people, out of which about 1 million have died globally.

It has been the need of the hour to come up with a treatment for this pandemic disease. Moreover, it is of utmost importance that all the information related to COVID -19 should be compiled in one place, a goal which this book will fulfill.

Though the tests for diagnosis of the infection have been developed in the start of the pandemic, there are still some issues in diagnosis, including the sensitivity of the best test available, *i.e.*, Real-Time Polymerase Chain Reaction.

The book is very well organized and has been divided into two parts; each part is comprised of 6 chapters and covers all the aspects of COVID-19 from the history to the treatment of the disease. Based on the best scientific studies available, the editors and authors have used their vast professional experience to discuss the all clinical aspects of COVID-19, including clinical presentation to diagnosis in the first part and treatment of COVID-19 in the second part, and I am very sure that this compendium will become the benchmark to refer to for any information required on COVID-19.

Whenever we write books, we must have in our minds, as clearly as possible, the affirmation of Carlyle Guerra de Macedo, who was the Director of Pan American Health Organization, relative to the responsibility of what is being published: “It must be remembered that behind each table, every report or material examined, there are lives, there are people, there is suffering, waiting for our efforts and human solidarity.” Both the parts of the book are very well organized, and the readers will get a mine of information available to date on COVID-19 in one place, and it would be helpful to both the clinicians and the lab professionals for day-to-day guidance in various matters. The monograph is comprehensive but is written in a lucid manner that is easy to grasp, and even complex topics are made simple for understanding.

I am also sure that as the knowledge of the virus evolves further, the authors will certainly keep updating the work from time to time, further adding to the importance of the book. I would like to congratulate the editors/authors for this tremendous effort, and I am very sure that this book will surely be of use to readers around the world and help them in the diagnosis and management of patients with COVID-19 and will also go a long way in the efforts to help fight the pandemic, which is being faced by the humanity now.

Prof. R. Sehgal
Department of Medical Parasitology
Chairperson Group D Departments
Postgraduate Institute of Medical Education & Research
Chandigarh-160012
India

PREFACE

The coronavirus disease 2019 (COVID-19) outbreak has spread throughout the globe and declared as a pandemic by the World Health Organization (WHO) on 11th March, 2020. Till date on 1st September 2020, there are more than 25,327,098 confirmed cases of COVID-19 worldwide and around 848,255 deaths have been reported. The clinicians and scientists across the globe need all the information on this pandemic disease on one platform. We have already discussed history, epidemiology, and diagnosis in part I of this book. Part II of the book “COVID-19: Diagnosis and Management” is a concise and visual reference for this viral disease. It will provide comprehensive knowledge that will cover all the aspects related to the prevention and treatment methodology of this communicable disease COVID-19.

Key Features:

1. Chapter wise description and segregation of all the areas of management of COVID-19.
2. Six chapters cover prevention and treatment aspects of COVID-19.
3. Multiple tables and figures summarize and highlight important points.
4. Covering all the aspects of COVID-19 making this a perfect textbook for Virologist and medical students.
5. A summary of the current standards for the evaluation and clinical management of COVID-19.
6. A detailed list of references, abbreviations and symbols.

This book is an essential reference for practicing and training virologists, pulmonologists, medical students, scientists working in various research labs, pharmaceutical and biotechnology industries on COVID-19.

Neeraj Mittal

Department of Endocrinology
Postgraduate Institute of Medical
Education and Research,
Chandigarh-160012
India

Sanjay Kumar Bhadada

Department of Endocrinology
Postgraduate Institute of Medical
Education and Research,
Chandigarh-160012
India

O. P. Katare

University Institute of Pharmaceutical Sciences
UGC Centre of Advanced Studies
Punjab University
Chandigarh-160014
India

Varun Garg

Department of Medical Affairs
Cadila Healthcare Limited
Ahmedabad 382421
Gujarat
India

List of Contributors

Aishwarya Joshi	Institute of Science, Nirma University, Ahmedabad, Gujarat, India
Amteshwar S. Jaggi	Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
Anamika Gautam	School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
Ankita Sood	School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
Archit Sood	Panjab University, Chandigarh, Punjab, India
Bimlesh Kumar	School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
Dhandeep Singh	Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
Dhara Patel	Topicals Research and Development, Amneal Pharmaceuticals, Piscataway, New Jersey, USA
Indu Melkani	School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
Kardam Joshi	Topicals Research and Development, Amneal Pharmaceuticals, Piscataway, New Jersey, USA
Kuldeep Kumar	Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
Mangesh Pradeep Kulkarni	School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
Manvendra Kumar	Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
Nikunj Tandel	Institute of Science, Nirma University, Ahmedabad, Gujarat, India
Nirmal Singh	Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
Pankaj Bhatia	Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
Pankaj Prashar	School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
Priya Sharma	Institute of Science, Nirma University, Ahmedabad, Gujarat, India
Raj Kumar	Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
Rajeev K. Tyagi	Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Biomedical Parasitology and Nano-immunology Lab, CSIR Institute of Microbial Technology (IMTECH), Chandigarh, India

iv

- Rajesh Kumar** School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
- Rimesh Pal** Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
- Sahil Arora** Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
- Sanjay Kumar Bhadada** Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
- Sheetu Wadhwa** School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
- Shivani Joshi** Institute of Science, Nirma University, Ahmedabad, Gujarat, India
- Sonal** Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India
- Soundappan Kathirvel** Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India

CHAPTER 1

Prevention of COVID-19: Facts to Overcome the Myths**Rajesh Kumar¹, Mangesh Pradeep Kulkarni¹, Sheetu Wadhwa¹ and Soundappan Kathirvel^{2,*}**¹ *School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India*² *Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India*

Abstract: The entire world has slowed down since the outbreak of a highly contagious virus, *i.e.*, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Extensive efforts are being made to reduce disease transmission, optimize the management strategy to reduce deaths and to come up with a vaccine as a preventive measure. Though several scientists across the globe are working tirelessly for developing an effective vaccine, it may still take several months to launch it successfully in the market. The behavioural interventions like maintenance of physical distancing (at least one meter), hand hygiene and cough etiquette, and use of personal protective equipment (PPE) are the currently available effective strategies to break the chain of disease transmission. All these interventions have been implemented at the population and individual level with or without linking with regulations. Based on the risk of exposure, provision and use of appropriate PPE is the need of the hour. The healthcare professionals working in COVID-19 areas have been recommended to use full PPE, which includes gloves, N-95 face masks, face shields, goggles, full-body gowns, and shoe covers. The general population has been asked to use homemade or triple-layered surgical masks in addition to the maintenance of physical distancing and hand hygiene. There are other additional strategies or measures which may or may not prevent the COVID-19 transmission. This chapter attempts to clarify the important and effective measures for the prevention of COVID-19 at the individual and community levels. It also tried to demystify the myths related to COVID-19.

Keywords: COVID-19, Diet, Disinfection, Face mask, Face shield, Filtering facepiece, Gloves, Hand hygiene, Home quarantine, Hydroxychloroquine, Institutional quarantine, N95 mask, Pandemic, Personal protective equipment, Physical distancing, Prevention, Sanitization, Screening, Transmission, Travel.

* **Corresponding author Soundappan Kathirvel:** Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India; Tel: +91-7087003412; E-mail: selvkathir@gmail.com

Neeraj Mittal, Sanjay Kumar Bhadada, O. P. Katare and Varun Garg (Eds.)
All rights reserved-© 2021 Bentham Science Publishers

INTRODUCTION

As it has been well-said, “Prevention is better than cure”, the same applies to the pandemic situation of COVID-19 as the causative virus is novel, and there is no specific treatment available. In this situation, only the preventive measures applicable to the community and individual level will help control the spread of infection and its impact. There are several preventive measures, specifically behavioural interventions like use of face masks or personal protective equipment, maintaining hand hygiene and physical distancing, practicing cough etiquette and others to contain the spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which have been discussed throughout this chapter (World Health Organization, 2020c). A thorough understanding of existing evidence on the mode of transmission of the infection is important to practice the preventive measures further.

The modes of transmission of coronavirus can be broadly categorized into two types. Direct transmission is characterized by close and direct contact of a healthy person with asymptomatic (less likely) or symptomatic COVID-19 patient, especially when a healthy individual comes into close contact (up to 2 meters) and has been exposed to the respiratory droplets (>5-10 μ m diameter) produced by sneezing, coughing, talking and other activities (Bai *et al.*, 2020). Indirect transmission of infection happens through contact with fomites. It is generated during sneezing and coughing, which may deposit on clothes and even surfaces or objects, making it viable for transmission (Guo *et al.*, 2020). However, the evidence on airborne transmission (through droplet nuclei-diameter <5 μ m) and transmission through the faeco-oral route is extremely limited. Though mother-to-child transmission is highly unlikely, the newborn baby is equally at risk of acquiring the disease like others for the person-to-person transmission through respiratory droplets or through contact with fomites (Sohrabi *et al.*, 2020; World Health Organization, 2020b). Table 1 summarizes the myths and facts related to the transmission of COVID-19 (Fong, 2020).

Table 1. COVID-19 transmission associated myths and facts.

Sr. No.	Myth	Fact
1	Coronavirus cannot be transmitted in extreme weathers like hot and humid or cold/freezing temperatures	There is no evidence till date that supports these theories and has been denied by WHO as well. The virus can stay viable even at significantly high temperatures, and this fact is supported by the increasing number of cases in India.
2	The novel coronavirus can spread through mosquitoes and houseflies	No. It is not. It is spread by respiratory droplets and through contacts.

(Table 1) cont....

Sr. No.	Myth	Fact
3	Only people with symptoms of this disease can spread it	Though transmission by an asymptomatic person is unlikely and no robust evidence available, it is possible.
4	Tobacco smoking prevents from corona infection	No. Actually, it may increase the risk of severe disease due to lowering lung function and hence increased mortality.
5	Being able to hold the breath for more than 10 seconds is a sign of the absence of virus	As more than 80% of patients present without any symptoms or with mild disease, they can hold the breath even during the acute stage.
6	Use of hand dryers can kill the virus	Hand dryers are not an effective disinfectant method against coronavirus. Alcohol-based sanitizers or hand wash using soap and water is an effective method.

MEASURES TO PREVENT THE SPREAD, ASSOCIATED MYTHS AND FACTS

The preventive measures ranged from using a simple face mask to using a full set (from head to toe) of personal protective equipment. Similarly, the preventive measures work together and effectively prevent the transmission of the disease like the use of face mask, physical distancing, maintenance of hand hygiene and others. Further, most of the measures are related to changing the behaviour and practice, some of which are linked with regulations.

Personal Protective Equipment (PPE)

The PPE can act as a physical barrier, or it is something that protects a person from any lethal biological agent when used properly (World Health Organization, 2020d).

PPE can be divided into various components, such as:

1. Head Cap/cover
2. Face Shield
3. Mask
4. Goggles
5. Gloves
6. Shoe Cover
7. Gowns or Coveralls

All the above-mentioned components together make a complete PPE, and a brief explanation on them, rationale of their use and the standards thereof are discussed below:

CHAPTER 2

Current Treatment Methods for Coronavirus Disease-19**Kuldeep Kumar¹, Sonal¹, Pankaj Bhatia¹, Dhandeep Singh¹, Amteshwar S. Jaggi¹ and Nirmal Singh^{1,*}**¹ Department of Pharmaceutical Sciences and Drug Research, Punjabi University Patiala, Patiala, India

Abstract: The coronavirus disease (COVID-19) pandemic outbreak has created health havoc all over the world. Till now, no definite treatment has been found to combat the COVID-19 outbreak, probably due to a poor understanding of the molecular mechanism of this infection. As it's a health devastating situation, so due to lack of proper time for research, clinicians all over the world are exploring the already approved drug such as lopinavir, ritonavir, chloroquine (CQ), hydroxychloroquine (HCQ), azithromycin (AZ), remdesivir, favipiravir, ribavirin, nitoxoxanide, interferon- α (IFN), arbidol, corticosteroids, ivermectin, teicoplanin, herbal drugs, *etc.* for antiviral activity. Previous studies suggest that these drugs act by different mechanisms such as prevention of entry and fusion of the virus with host cell by blocking angiotensin-converting enzyme-2 (ACE-2) receptor and increasing endosomal pH respectively, inhibition of RNA polymerase and protease enzyme, inhibition of inflammatory pathway by blocking toll-like receptors (TLR's), inhibition of RNA synthesis, interference of glycosylation of cellular receptor, suppression of immune response, *etc.* Besides these drugs, few humanized monoclonal antibodies such as tocilizumab and sarilumab are also shown to be effective against COVID-19 by blocking interleukin-6 (IL-6) receptors. In addition to these drugs, convalescent plasma therapy is also being used to treat COVID-19 patients. Focus is on the development of a vaccine for COVID-19 at the earliest and indeed, many vaccines are in various stages of the development process, with some under clinical trials. This review gives an exhaustive view of current therapeutic strategies for the management of COVID-19.

Keywords: ACE-2, Arbidol, Azithromycin, COVID-19, Corticosteroids, Favipiravir, Hydroxychloroquine, IL-6, Immune response, Interferon- α , Ivermectin, Lopinavir, Monoclonal antibodies, Plasma therapy, Protease, Remdesivir, Ribavirin, Ritonavir, RNA polymerase, TLR's, Tocilizumab.

* Corresponding author Nirmal Singh: Department of Pharmaceutical Sciences and Drug Research, Punjabi University Patiala, Patiala, India; Tel: 91-9815129884; E-mail: nirmal_puru@rediffmail.com

Neeraj Mittal, Sanjay Kumar Bhadada, O. P. Katare and Varun Garg (Eds.)
All rights reserved-© 2021 Bentham Science Publishers

INTRODUCTION

The coronavirus disease (COVID-19), also referred as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been the major health outbreak nowadays. This virus was firstly detected from Wuhan city of China in December, 2019, and now it has been spread worldwide (more than 190 countries) (Wang *et al.*, 2020). Till the end of May 2020, over 6 million human beings are reported to be affected and nearly half a million deaths have been reported due to COVID-19. Health machinery all over the world is trying its very best to combat this pandemic and facing a real challenge to tide over this crisis. Till today, no definite treatment has been found to combat this COVID-19 outbreak. Besides probationary drug therapy, some preventive, supportive, and precautionary measures such as self-isolation, social distancing, avoid unnecessary travel and crowded places are being advised and exercised to prevent the spread of this devastating infection (Chen *et al.*, 2020). Due to lack of time and a health emergency, clinicians are exploring the already approved drug for anti-viral activity (Savarino *et al.*, 2006; Rolain *et al.*, 2007; Mullard, 2012; Yan *et al.*, 2013; Agostini *et al.*, 2018; Bleibtreu *et al.*, 2018; Colson *et al.*, 2020; Cao *et al.*, 2020). In the wake of this, a number of drugs such as lopinavir, ritonavir (Cao *et al.*, 2020), chloroquine (CQ), hydroxychloroquine (HCQ) (Savarino *et al.*, 2006; Yan *et al.*, 2013), remdesivir (Agostini *et al.*, 2018), favipiravir, ribavirin, interferons (IFN's), corticosteroids, oseltamivir (Bleibtreu *et al.*, 2018), *etc.* have been tested on COVID-19 infected patients and are in current practice but with variable success. Critical insight into various treatment methods currently being employed to manage COVID-19 infection is being given in this review.

OVERVIEW OF VARIOUS TREATMENT STRATEGIES FOR COVID-19

Hydroxychloroquine

Cinchona bark and its derived constituents are considered as the primary treatment for malaria (Ruiz-Irastorza and Khamashta, 2008). CQ, a 9-aminoquinoline, has been used as the most effective anti-malarial compound (Wellems and Plowe, 2001). HCQ (7-Chloro-4-[4-(N-ethyl-N-hydroxymethylamino)-1-methylbutylamino]quinoline sulfate) is a hydroxyl analogue of CQ that is a more safe and efficacious molecule (Sperber *et al.*, 1995). HCQ is a widely used clinical agent not only in the treatment of malaria but also for many other disorders such as fungal infections (Byrd and Horwitz, 1991; Henriot *et al.*, 2013), rheumatoid arthritis (RA) (Rainsford *et al.*, 2015), systemic lupus erythematosus (SLE) (Jessop *et al.*, 2001; Rainsford *et al.*, 2015), sjogran's syndrome (Oxholm *et al.*, 1998) and polymorphic light eruption (PLE) (Pareek *et al.*, 2008). In addition to the above disorders, HCQ is also demonstrated to

possess anti-viral activity and has been used clinically for the treatment of several viral infections such as human immunodeficiency virus-1 (HIV-1) (Chiang *et al.*, 1996), Zika virus (ZIKV) (Kumar *et al.*, 2018), dengue virus (DENV) (Wang *et al.*, 2014) and severe acute respiratory syndrome coronavirus (SARS-Co-V) (Vincent *et al.*, 2005). HCQ has efficient absorption after oral administration with peak plasma concentration reaching after 2-3.5 hours and it has an elimination half-life around 22-45 days (Tett *et al.*, 1989; Lim *et al.*, 2009).

HCQ in Treatment of COVID-19

HCQ has become a molecule of the moment because of its utility in managing COVID-19 infection. Many *in-vitro* and controlled and uncontrolled clinical trials have substantiated the activity of HCQ against COVID-19 (Gautret *et al.*, 2020; Liu *et al.*, 2020; Yao *et al.*, 2020). These *in-vitro* reports are further supported by many clinical trial studies carried out, and being conducted in different countries such as China, U.S, Europe, *etc.* (Gao and Yang, 2020; NCT04261517; NCT04307693). Therefore, HCQ has seen variable success in these clinical trials. In a non-randomized, open-label clinical trial conducted out in France, 20 patients of COVID-19 were administered with HCQ at the dose of 200 mg three times daily (TID) and were compared with another group of patients who received supportive care. It was concluded that all patients well tolerated the HCQ and showed fast clearance of virus (Gautret *et al.*, 2020). Moreover, another study conducted in China reported that HCQ at the dose of 400 mg daily did not show any clinical benefits in mild COVID-19 patients (Chen *et al.*, 2020). Another parallel study from China conducted on more than 100 patients of COVID-19 gave evidence of less severe pneumonia, improvement in lung imaging and decreased disease duration in comparison to control group patients after receiving HCQ (Gao and Yang, 2020) and it was also documented that the treatment was safe. This study gave confidence to the experts in China to recommend HCQ at the dose of 500 mg twice daily for 10 days to mild, moderate, and severe patients of COVID-19 (Zhonghua *et al.*, 2020).

Probable Mechanism of HCQ in Treatment of COVID-19

It is being hypothesized that HCQ acts by inhibiting the replication of viral nucleic acid, glycosylation of viral proteins, assembly and transport of virus and release of virus molecule to achieve its anti-viral activity (Fox, 1993; Wang *et al.*, 2015; Kumar *et al.*, 2018) (Fig. 1). It is suggested that HCQ has an immunomodulatory effect, which further helps in decreasing the elevated level of cytokines, interleukin-6 (IL-6), and IL-10, which are primary contributors to multi-organ failure and death in COVID-19 patients (Chen *et al.*, 2020; Huang *et al.*, 2020). It is also being considered from the previous history of HCQ for

COVID-19 and Mortality

Rimesh Pal¹ and Sanjay Kumar Bhadada^{1,*}

¹ Department of Endocrinology, Post Graduate Institute of Medical Education and Research Chandigarh-160012, India

Abstract: The novel coronavirus disease (COVID-19) has scourged the world ever since its outbreak in December 2019 in Wuhan, China. The disease tends to be asymptomatic or mild in nearly 80% of the patients. However, around 5% of the patients tend to have critical disease complicated by acute respiratory distress syndrome (ARDS), shock and multiple organ failure. Mortality in COVID-19, as represented by the case-fatality rate (CFR), is around 6% (as of June 4, 2020). The CFR of COVID-19 is lower as compared to other coronavirus-related diseases like the Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome (MERS), however, it is likely to increase as we reach the end of the pandemic. The CFR also varies widely from one nation to another with the maximum mortality being hitherto reported from the European nations and the least from Singapore, Cambodia, Vietnam and Iceland. The common causes of death in COVID-19 include respiratory failure, consequently leading to ARDS, pulmonary thromboembolism, shock and multiple organ failure. Advancing age and presence of comorbid illness are consistently associated with an increased risk of death, while certain biochemical and hematological parameters, notably C-reactive protein, IL-6, cardiac troponin, D-dimer and absolute count can also help predict mortality in patients with COVID-19.

Keywords: ACE2, ARDS, Case-fatality rate, Comorbidities, COVID-19, Cytokine storm, D-dimer, Death, Diabetes mellitus, Hypertension, IL-6, Lymphopenia, Mortality, Mortality rate, Novel coronavirus disease, Old age, SARS-CoV-2, Shock, Thromboembolism, Troponin.

INTRODUCTION

An unprecedented outbreak of ‘pneumonia of unknown cause’ emerged in the Wuhan City of China in December 2019 (Pneumonia of unknown cause – China, 2020). The patients presented with clinical symptoms of fever, dry cough, dyspnea, and bilateral lung infiltrates on imaging. Cases were claimed to be all

* Corresponding author Sanjay Kumar Bhadada: Department of Endocrinology, Post Graduate Institute of Medical Education and Research Chandigarh-160012, India; E-mail: bhadadask@rediffmail.com

linked to the Wuhan's Seafood Wholesale Market, which trades in fish and a wide variety of live animal species, including poultry, bats, rats, marmots, and snakes. The causative pathogen was identified from throat swab samples collected from the patients and was subsequently named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The disease was named novel coronavirus disease (COVID-19) by the World Health Organization (WHO). With the increase in the number of cases outside China, the WHO declared the outbreak of COVID-19 to be a Public Health Emergency of International Concern, posing a high risk to countries with vulnerable health systems on January 30, 2020. Subsequently, with the emergence of new epicenters in Italy and Iran, COVID-19 was declared a pandemic on March 11, 2020.

Ever since its outbreak, COVID-19 has scourged the world, affecting over 6.2 million people, inflicting more than 379000 casualties worldwide (Coronavirus disease (COVID-19) Situation Report – 135, 2020). Hitherto, the maximum number of cases has been reported from the United States of America, Brazil, Russia, the United Kingdom, Spain, Italy, India, Germany, Peru, Turkey, Iran and France (Coronavirus (COVID-19), 2020). The inherent ability of SARS-CoV-2 to withstand extremes of the ambient environment and its remarkable stability on inanimate objects and surfaces make it an ideal pathogen for human-to-human transmission. The basic reproductive number (R_0) of COVID-19, defined as the average number of secondary cases attributable to infection by an index case after that case is introduced into a susceptible population, is high, ranging from 1.5 to 6.68 with a mean of 3.28 (Liu *et al.*, 2020). The high R_0 of SARS-CoV-2 has accounted for the rapid increase in the number of COVID-19 cases worldwide. In addition, there have been instances of super-spreader events, in which an individual, who may or not be symptomatic, infects a large number of susceptible subjects (Coronavirus disease 2019 (COVID-19) Situation Report – 24, 2020.; Coronavirus disease 2019 (COVID-19) Situation Report – 36, 2020). In fact, the outbreak of COVID-19 in Wuhan might have been a super-spreader event as it had coincided with one of the world's largest mass gathering, the Chinese Spring Festival (Ebrahim and Memish, 2020).

Despite being highly contagious, more than 80% of patients with COVID-19 are either asymptomatic (no pneumonia) or have mild symptoms (mild pneumonia). Only 14% of patients develop the severe disease; the rest 5% develop critical disease manifesting as respiratory failure, septic shock, and/or multiple organ dysfunction or failure (Wu and McGoogan, 2020). Case-fatality rates in COVID-19 have been highly variable, ranging from as low as 0.5% to as high as 21.8% (Mortality Risk of COVID-19, 2020). Nevertheless, advancing age and the presence of underlying co-morbidities have been consistently associated with increased mortality in COVID-19. In addition, certain biochemical parameters

have emerged as potential predictors of mortality in COVID-19.

Herein, we have discussed in detail the multiple aspects of mortality in relation to COVID-19.

REPRESENTING MORTALITY – MORTALITY RATE VS. CASE-FATALITY RATE

Often the terms mortality rate and case-fatality rates are used interchangeably. Although both the parameters are used to define death rates, the two are not synonymous. According to the *Dictionary of Epidemiology*, the mortality rate is defined as “an estimate of the portion of a population that dies during a specified period”. Going by the definition, the mortality rate should be ideally expressed as the number of deaths occurring per 100000 population per year, rather than representing the figure as a percentage. On the other hand, the case-fatality rate (CFR) is defined as “the proportion of cases of a specified condition that are fatal within a specified time” (Spychalski *et al.*, 2020). Accordingly, most of the estimates of death expressed as a percentage are case-fatality rates rather than mortality rates. We have referred to CFR throughout the subsequent discussion unless otherwise specified.

FALLACIES IN ESTIMATING MORTALITY USING CASE-FATALITY RATE

Case-fatality rates amid an ongoing pandemic should be interpreted with caution. The CFR is affected by the total number of cases (the denominator) as much as it is affected by the actual number of deaths (the numerator). For example, in countries where massive population screening has been undertaken, as in Switzerland and South Korea, case-fatality rates are less than 1%, as the denominator includes a large number of mild/asymptomatic cases. However, in countries where only symptomatic patients or those requiring hospital admissions are being screened, as in Italy and Spain, case-fatality rates have exceeded 5%, because the denominator is much smaller (Vincent and Taccone, 2020). Besides, the CFR might be over or underestimated based on how a ‘case’ is defined. During an ongoing epidemic, cases might be defined either as total cases (every confirmed case) or as closed cases (only those who have recovered or died). Hence, the denominator for calculating CFR might be either of these numbers. In the initial phase of an epidemic, the number of closed cases is relatively small, and so the CFR calculated per closed cases is an overestimate. By contrast, when the CFR is calculated per total cases, the whole calculation becomes an underestimate. As an example, early in the course of COVID-19, even before it was declared a pandemic, the WHO had opined on March 3, 2020, that the global COVID-19 CFR was 3.4% (WHO Director-General’s opening remarks at the

Long Term Complications of COVID-19

Ankita Sood¹, Bimlesh Kumar^{1,*}, Indu Melkani¹, Archit Sood², Pankaj Prashar¹, Anamika Gautam¹, Kardam Joshi³ and Dhara Patel³

¹ School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India

² Punjab University, Chandigarh, Punjab, India

³ Topicals Research and Development, Amneal Pharmaceuticals, Piscataway, New Jersey, USA

Abstract: Coronavirus disease 2019 (COVID-19) is an acute respiratory illness. It is caused by a novel coronavirus (SARS-CoV-2). It has gained widespread recognition after it originated from China. The World Health Organisation (WHO) declared the outbreak of COVID-19 as an international public health emergency. Patients of COVID-19 develop long-time complications along with severe health problems as it majorly affects the respiratory system, utilizing angiotensin-converting enzyme 2. Characteristic symptoms include fever, cough, and dyspnea, although some patients may be asymptomatic. People need extensive care to be protected from anxiety and depression. This outbreak harmed various organ systems and led to the development of long-term complications such as respiratory failure, pneumonia, pancreatic complications, cardiac injury, secondary infections, renal disorders, disseminated intravascular coagulation, and rhabdomyolysis. Individuals with comorbidities are at higher risk of illness and mortality. The risk is also increasing in older people, especially people the age of 60-80 years or more. The most prevalent comorbidities are asthma, neurologic disorders, diabetes, obesity, cardiovascular disease, and malignancy/hematologic conditions. As there is no specific treatment available so far, therefore complications of this disease are also increased by the use of non-specific drugs. The recovery of these patients is another major challenge for health care professionals. So in this chapter, we will discuss long-term complications associated with COVID-19.

Keywords: Cardiovascular diseases, Coronavirus, COVID-19, Diabetes, Mortality, Neurological effect, Pandemic, Renal effect, Respiratory effect, Rheumatoid arthritis.

INTRODUCTION

The latest coronavirus 2019 (2019-nCoV) or SARS-COV-2, a respiratory synd-

* **Corresponding author Bimlesh Kumar:** School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar, Punjab, India; Fax: +91-1824-240830; Tel: +919872260354; E-mails: bimlesh1Pharm@gmail.com and bimlesh.12474@lpu.co.in

rome, has rapidly spread from the Wuhan Town of Hubei, China, to the rest of the world. Coronavirus 2019 (COVID-19) is a consequence of severe acute respiratory syndrome that is now a significant concern for global public safety and local communities (Li *et al.*, 2020b). More importantly, following considerable initiatives and a rising number of remedies in China, the disease has now started to spread from China to Europe, North America, and other Asian countries (Wu and McGoogan, 2020). Coronavirus is a positive-sense RNA virus with spike-like projections having a diameter of about 60-140 nm. Under the electron microscope, it shows its crown-like appearance; thus, the term coronavirus has been used for it. There are four different types of coronaviruses (HKU1, NL63, 229E, and OC43). They are responsible for causing mild respiratory diseases in humans (Singhal, 2020). If an individual is suffering from COVID-19, their clinical symptoms range from asymptomatic disease to respiratory failure and finally leading to multiple organ dysfunction. Such kind of developed complication leads to the death of patients. The commonest health symptoms in COVID-19 include fever, cough, headache, sore throat, myalgia, fatigue, and respiratory illness. Conjunctivitis is also reported in some of the patients of COVID-19. Therefore it is difficult to distinguish this from other respiratory infections (Lima, 2020).

By the completion of the first week after the reports of the spread of COVID-19, cases of pneumonia, respiratory failure, and death were reported. This breakthrough is related to the significant increase in inflammatory cytokines like IL2, IL7, IL10, and TNF α . A person of any age group is susceptible to this disease. Symptomatic patients of COVID-19 release their large droplets through cough and sneezing. These incidences cause the spreading of infection of COVID-19. This spread of infection may also arise from asymptomatic individuals even before the occurrence of symptoms. In contrast with the mouth, higher viral loads have been observed in the nasal cavity. Moreover, patients can remain contagious as long as the virus survives in them, and also after they are fully recovered (Wu *et al.*, 2020a, Singhal, 2020). The development of such a condition of infection is due to the passing of the virus through the mucous membranes. It enters the human body through nasal and larynx mucosa. After that, it enters into the lungs through the respiratory tract. As a result of this, fever and cough are the most common symptoms of infection to appear. Further, it causes viremia when it invades into peripheral blood through the lungs. Then the virus attacks the targeting organs that express Angiotensin-converting enzyme 2 (ACE2), such as the lungs, heart, renal, gastrointestinal tract. The fecal samples have also been found to have evidence of SARS-CoV-2. The reason behind this detection is due to the entry of this virus takes place through the lung to blood and then it propagates from the blood to the intestines. During the process of infection, the count of white blood cells is normally or slightly less in peripheral blood at an

early stage only. But as time progresses the lymphopenia is observed in patients (Cheng *et al.*, 2020a). The critical stage is appearing in this disease as a reduction of B lymphocyte occurs in the early stage of this disease only, which may affect the production of antibodies. It is also noticed that the patients having a severe stage of the COVID-19 reduction of lymphocytes significantly takes place (Cheng *et al.*, 2020a). The increased level of neutrophils, D-Dimer, blood urea nitrogen, and creatinine was reported in non-survivors than the survivors. Based on these recently reported facts and assumptions, the clinical stages can be divided as follows:

- a. The viremia stage.
- b. The acute stage (pneumonia phase) and
- c. The recovery stage (Guan *et al.*, 2020, Wang *et al.*, 2020a, Letko *et al.*, 2020).

The coronavirus disease pandemic is causing significant morbidity and mortality in patients having a long history of any diseases associated with primary disease. Older age, diabetes mellitus, cancer, chronic kidney disease, rheumatoid arthritis, hypertension, and obesity greatly raise the likelihood of hospitalization and mortality in patients with COVID-19 (Guo *et al.*, 2020a). In this context, we explore the long-term complications of COVID-19 in patients suffering from various diseases.

LONG TERM COMPLICATIONS OF COVID-19

The meaning of the long history of diseases is chronic complications and it can be defined as the clinical state of suffering that tends to arise over the years and persists for decades. In this, patients used to suffer from not only the various complications of primary diseases but also secondary or multiple diseased states. Even though a large number of people are impacted by the COVID-19 pandemic, the most vulnerable are the aged, under-represented minorities, and underlying diseases. The increasing consumption of an unhealthy diet with excessive amounts of saturated fats, carbohydrates, and sugar persuade the pervasiveness of obesity and type 2 kind of diabetes and may raise the likelihood of seriousness of COVID-19 disease and its mortality (Butler and Barrientos, 2020). A healthy diet is very important for the development of immunity. Immunity and lifestyle (daily habit of food intake) are related to each other. So if the person taking an unhealthy diet or careless about the daily nutritious diet intake invites stimulation of the innate immune response and impairment of adaptive immunity which is inducing persistent inflammation, and finally brings disruption of the host defense system. Besides, the long-standing impact of peripheral inflammation induced by COVID-19 contributes to chronic medical disorders such as neurodegenerative disorder and dementia. These conditions are developed possibly through

Vaccine Development

Priya Sharma^{1,#}, Shivani Joshi^{1,#}, Aishwarya Joshi¹, Nikunj Tandel¹ and Rajeev K. Tyagi^{2,*}

¹ Institute of Science, Nirma University, Ahmedabad, Gujarat, India

² Biomedical Parasitology and Nano-immunology Lab, CSIR Institute of Microbial Technology (IMTECH), Chandigarh, India

Abstract: The current COVID-19 pandemic is a wake-up call pointing towards the vulnerability of humankind as it has outstretched its arms to almost all the continents, sparing few socially isolated ones. The highly contagious nature, ultra-stable genetic makeup, novel modifications in open reading frame (ORF) region, air-borne route of transmission, and ability to cross the species barrier prove the potential of COVID-19 to elicit the global pandemic situation. In current times, when even known antibiotics for combating several diseases are being rendered inefficacious owing to the rising multidrug resistance among pathogenic strains, the panacea to a wide array of diseases can be vaccination. A prominent characteristic for COVID-19 vaccine development is that numerous technologies from lipid nanoparticle (LNP)-encapsulation, dendritic cells (DCs)-based vaccines, antigen-presenting cells (artificial-APCs)-based vaccines, and DNA plasmid-based platforms to viral vector approaches are being evaluated for the cause. Certain vaccine development technologies may be better suited for some parts of the global population, while others may prove to be more efficacious for the other population subtypes. This may not only be arising due to geographical or ethnic distinctions, but also physiological differences such as the presence of comorbidities, immune profile of subjects, *etc.* In this chapter, we attempt to bring forth the various approaches or molecular platforms that have been taken up or proposed for the development of a vaccine against coronavirus disease. We also attempt to elaborate on the pros and cons associated with each of the approaches that may be feasible due to the distinctions in the various population subtypes.

Keywords: Air-borne transmission, Animal model, APCs-based vaccines, Artificial-APCs, Comorbidities, COVID-19, DCs-based vaccines, DNA plasmid-based platforms, Genetic makeup multidrug resistance, Global population, Immune profile, Lipid nanoparticle (LNP), Molecular platforms, Novel modifications, Pathogenic strains, Physiological differences, Population subtypes, Vaccine development, Viral vector approaches.

* Corresponding author Rajeev K. Tyagi: Biomedical Parasitology and Nano-immunology Lab, CSIR Institute of Microbial Technology (IMTECH), Chandigarh, India; Tel: 91-172-6665278; E-mails: rajeevtyagi@imtech.res.in and rajeev.gru@gmail.com

Equal Contribution

COVID-19: VACCINE DEVELOPMENT

Over the past decade, vaccine technology has undergone immense evolution, and different approaches for the development of vaccines against viruses and other pathogens have emerged. The advancement has enabled researchers to develop a wide range of vaccine candidates such as nucleic acid-based (DNA/RNA) vaccines, recombinant protein-based vaccines, and viral-vectored vaccines, *etc.* The rapid revelation of the genetic map of the SARS-CoV-2 viral genome has opened avenues facilitating several vaccine development programs against COVID-19 (Liu *et al.*, 2017). As of the current scenario, there is no antiviral drug available as a frontline treatment for the disease. To conquer the threat of COVID-19, urgent therapeutic intervention is the need of the hour, and therefore several strategies for vaccine development, besides drug development, have been initiated (Taghizadeh-Hesary and Akbari, 2020). As a result of these, there are currently 115 potential vaccine candidates across the globe, 78 of which are established as active projects; 5 among those candidates have already successfully crossed the pre-clinical stages (Grifoni *et al.*, 2020).

It is a remarkable feature of research & development for the COVID-19 vaccine that a wide assortment of platforms is being tried out. As mentioned earlier, platforms including nucleic acid-based vaccines, recombinant proteins, live attenuated virus, as well as inactivated virus-based approaches, alongside viral peptides, virus-like particles (VLPs), and replicating/non-replicating viral vectors are being explored for the development of SARS-CoV-2 vaccine. It is advantageous that several approaches have been taken up, especially concerning the fact that certain immunization technologies may be efficient for a specific group of population. This specific effectiveness relates not only in terms of age, ethnic, or epigenetic differences but also correlates to the physiological variances such as the presence of certain comorbidities (Grifoni *et al.*, 2020). The extensive study on the SARS-CoV-2 virus and its genome has revealed potential targets for vaccines and drug interventions. Bioinformatics and computational tools have a significant role to play in recognizing the most competent targets. A large number of databases have been created for easy and correct identification of potential vaccine targets (Taghizadeh-Hesary and Akbari, 2020). The characterization of the SARS-CoV-2 spike glycoprotein has enabled the researchers to identify precise immunogenic epitopes that can be taken into account for vaccine development. Their extensive analysis pointed out 13 and 3 epitopes for MHC-I & II respectively on the spike glycoprotein of the virus that can be incorporated in the formulation of a multi-epitopic peptide vaccine. Further, these candidate epitopes have been assessed for their effective immunogenicity through molecular docking with TLR-5; However, *in vitro* and *in vivo* validations are required to confirm the potential of this vaccine candidate. The fact that the SARS-CoV-2

virus is proximally related to MERS and SARS viruses which has allowed researchers to utilize structure-function comparisons to hasten the process of recognizing potential vaccine candidates (Taghizadeh-Hesary and Akbari, 2020).

Nevertheless, there are certain challenges associated with vaccine development. After the identification and *in silico* validation of a vaccine candidate, it is taken forward for a formulation, which itself is a long process. In the first phase, it passes through the rigorous tests for the efficacy and safety in animal models. It is safe to consider the fact that developing suitable animal models for SARS-CoV-2 may be a challenge in itself, as the virus is known to not propagate in wild-type mice; Further, this virus only induces a mild form of the disease in transgenic animals that are engineered to express human ACE2 (Liu *et al.*, 2017). However, even in the absence of animal models, it is not entirely impossible to assess the vaccine candidate. Serum obtained from the immunized animals can be further validated through *in vitro* testing *via* neutralization assays. The remaining part of this tier is to gauge the vaccine candidate for its safety in animals in a manner acquiescent to the GLP (Good Laboratory Practices) guidelines and usually lasts for a minimum period of 6 months. This is followed by the production of vaccine compliant to current good manufacturing practice (cGMP) that assures the quality and safety of the vaccine. The second tier that includes the clinical phase I (small trials to evaluate safety on humans), phase II (aimed at establishing dosages and formulations to substantiate efficacy in humans), and phase III trials (both efficacy and safety of the vaccine candidate should be validated in a larger population). However, in certain unexpected conditions, such as during the pandemic of COVID-19, the guidelines may be flexible, and the process for approval may be accelerated with necessary precautions taken.

COVID-19 VACCINE DEVELOPMENT: MODULATING THE HOST IMMUNE SYSTEM

To understand the mechanisms of immunization that can facilitate the modulation of the host immune system in response to SARS-CoV-2, it is substantial that we apprehend the natural manifestations that the host system gradually adapts to modulate the response to the viral infection. The virus can successfully invade the cells which express the ACE2 and TMPRSS2 (transmembrane protease serine 2) surface receptors. Once the cells get infected, the viral genome undergoes active replication followed by cascade steps and releases the copies of the packaged virus from the infected cell. It is followed by pyroptosis, a mechanism through which cells release the damage-associated molecular patterns (DAMPs). These DAMPs are recognized by surrounding cells such as epithelial cells, endothelial cells, and alveolar macrophages, which in turn trigger a pro-inflammatory condition in the milieu by inducing the generation of cytokines and chemokines,

The Future of COVID-19 Treatment

Sahil Arora^{1,#}, Manvendra Kumar^{1,#}, Gaurav Joshi^{1,*} and Raj Kumar^{1,*}

¹ Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India

Abstract: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or coronavirus disease or COVID-19 is a disease that has led to colossal mortality worldwide. The fast spread of this disease has caused havoc and panic among individuals, which has further worsened with the unavailability of vaccines or some proven drug regime. To date, only 12 new antiviral drugs have been approved by the FDA (8 against hepatitis C virus (2 in combinations for HIV). Thus, it becomes of utmost importance to identify drugs for new and re-emerging viruses, including the coronavirus. Considering the quest, we have put forth this book chapter to update readers about current repurposed and experimental drugs for this novel coronavirus. The viral lifecycle assisted in providing vital potential targets for drug therapy. The present chapter also deals with the existing mechanism of action of the drugs, their category, and clinical data reported.

Keywords: ACE2 inhibitors, Antiarrhythmic, Antibacterial, Anticancer, Anticoagulants, Antidiabetic, Antifungal, Anti-inflammatory, Antimalarial, Antioxidant, Antiparasitic, Antiprotozoal, Antiviral, Chelating agents, COVID-19, Drug repurposing, Natural products, Psychotropics, RAAS-ACE-ARBs inhibitors, SARS-CoV-2.

INTRODUCTION

Considering the COVID-19 pandemic, it becomes of utmost importance to identify drugs that possess potential and efficacy in treating COVID-19 disease (Mercorelli *et al.*, 2018, Cupertino *et al.*, 2020). The COVID-19 disease is notably marked with attacks at the lower respiratory system that leads to viral pneumonia along with affecting kidney, liver, heart, central nervous system, and gastrointestinal system leading to multiple organ failure responsible for high morbidity (Su *et al.*, 2016, Zhu *et al.*, 2020). Recently, drug target validation in

* Corresponding authors Gaurav Joshi and Raj Kumar: Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India;
E-mails: garvpharma29@gmail.com and raj.khunger@gmail.com; raj.khunger@cup.edu.in

Both, the authors, contributed equally

SAR-CoV-2 has led to the identification of newer targets for therapeutic development (Mani *et al.*, 2019). To date, (June 4, 2020) 53 targets have been identified.

The important one includes non-structural proteins, spike proteins, membrane protein, nucleocapsid proteins, *etc.* The identified targets/proteins possess enzymatic activities and catalyze the virus-cell cycle by hijacking the host cells.

The virus division cycle (Fig. 1) consists of six phases, which include attachment of virus with the host cell receptors, allowing its entry, followed by translation, replication, and release, and the subsequent damage resulting from the compromised immune system.




Fig. (1). SARS-CoV-2 life cycle in the host cell. The cycle consists of critical phases starting from the attachment of the virus with host cell receptors, endocytosis, proteolysis, translation, replication, maturation, and release of mature virions that ultimately are shredded, leading to subsequent damage of the organ system resulting from the compromised immune system.

Taking into account the reported interaction pattern of the virus with the host cell, many drugs have been repurposed so far. The drugs are currently under various clinical trials, and their efficacy and potential are still awaited. Drug repurposing characterizes a practical drug discovery approach from already known drugs (for different therapeutic use). It could minimize the time and decrease the cost associated with the *de novo* drug discovery (Zhou *et al.*, 2020b). This practice has been gaining popularity in recent years (Aubé, 2012). The approved drug requires regulatory approval for novel therapeutic applications which were already optimized for efficacy and safety in a particular disease (Chong *et al.*, 2007). The strategy used for drug repurposing involves identification of ligand for an indication of interest, drug assessment in preclinical models by mechanistic interpretation, efficacy evaluation in phase II clinical trials. There are various approaches used for drug repurposing, such as computational and experimental approaches. Computational approaches include molecular docking (Kitchen *et al.*, 2004), signature matching (Hieronymus *et al.*, 2006), pathway mapping (Smith *et al.*, 2012), genetic association (Sanseau *et al.*, 2012), novel data sources (Althouse *et al.*, 2015), and retrospective clinical analysis (Hurle *et al.*, 2013). Experimental approaches, such as phenotypic screening (Moffat *et al.*, 2017) and binding assays, are involved in the identification of relevant target interactions (Molina *et al.*, 2013). Some of the success stories of drug repurposing in other diseases include the use of paromomycin (from antibiotic in acute and chronic intestinal amebiasis to visceral and cutaneous leishmaniasis) (Ben Salah *et al.*, 2013), doxycycline (from bacteriostatic to antimalarial) (Tan *et al.*, 2011), miltefosine (from cancer to leishmaniasis) (Dorlo *et al.*, 2012), allopurinol (from cancer to gout) (Yasuda *et al.*, 2008), amantadine (from antiviral to tremors) (Gironell *et al.*, 2006), atomoxetine (from antidepressant to attention deficit hyperactivity disorder) (Turgay, 2005), colchicine (from gout to post-pericardiotomy syndrome) (Imazio *et al.*, 2010), and bromocriptine (from Parkinson's disease to type 2 diabetes) (Shaughnessy, 2011). Some examples of repurposed drugs used for the previous counterpart of SARS-CoV-2, *i.e.*, SARS and Middle East Respiratory Syndrome (MERS), include nitazoxanide (Rossignol, 2016), hydroxychloroquine (Zhou *et al.*, 2020a), emetine (Sharif-Yakan *et al.*, 2014), terconazole (Omrani *et al.*, 2015), lopinavir (Chan *et al.*, 2015), ritonavir (Chan *et al.*, 2015), ribavirin (Khalili *et al.*, 2020), homoharringtonine (Mustafa *et al.*, 2018), *etc.* The drugs for repurposing for the treatment of COVID-19 disease fall into multiple categories possessing various essential mechanisms. The essential categories include antivirals, anticancer, Angiotensin Converting Enzyme-Renin-Angiotensin-Aldosterone system (ACE-RAAS) inhibitors, anti-inflammatory, immune modulators, antibiotics, antirheumatics, *etc.* Besides this, some of the herbal drugs and nutraceuticals have also exhibited significant inhibitory potential against SARS-CoV-2 (Khan *et al.*, 2020, Liu *et al.*, 2020b).

SUBJECT INDEX

A

- Acid 176, 185, 187
 - tranexamic 185, 187
 - valproic 176
- Activation 31, 42, 43, 51, 101, 128, 134, 179, 183, 185, 187
 - lymphocyte 179
 - signaling-mediated 128
- Activities 20, 37, 42, 48, 51, 115, 128, 146, 170
 - anti-inflammatory 42
 - anti-microbial 20
 - anti-SARS 48
 - decreased thymic 115
 - enzymatic 170
 - global R&D 146
 - immune regulatory 51
 - phagocytic 128
 - polymerase 37
 - polymerase inhibitory 37
- Acute 109, 185
 - iron toxicity 185
 - virus infection 109
- Acute respiratory 31, 43, 71, 78, 82, 83, 84, 85, 86, 87, 88, 112, 113, 114, 178, 184, 185
 - distress syndrome (ARDS) 71, 78, 82, 83, 84, 85, 86, 87, 88, 112, 113, 114, 178, 184, 185
- Adaptive immunity 42, 52, 98, 128, 129, 132
- Adenosine triphosphate, active 32
- Adenovirus 134, 152, 154
 - based vaccine 154
 - vectors 134
- Adjuvant recombinant vaccine 149
- Alanine transaminase 80, 86
- Albumin therapy 137
- Alcohol 10, 13, 21
 - ingesting 21
 - isopropyl 10
- Alcohol-based 3, 10, 12
 - hand rub 10
 - sanitizers 3, 12
- Aldosterone system 171
- Alveolar 135, 141
 - cavities 141
 - epithilia 141
 - lavage 135
- Analysis 79, 87, 103, 109, 171
 - autopsy 109
 - longitudinal multi-center 103
 - prognosis 79
 - retrospective clinical 171
 - single-center retrospective 87
- Angiotensin-converting enzyme 31, 43, 83, 96, 97, 171
 - inhibitors 83
 - renin 171
- Angiotensin-receptor blockers (ARBs) 52, 83
- Antibiotics 37, 125, 171
 - glycopeptides 37
 - macrolide 34
- Antibodies 44, 48, 131, 133, 136, 138, 145, 158, 159, 189
 - generating plasma 145
 - neutralizing 44, 131
 - producing anti-DNA 136
- Anticancer 169, 171, 179, 180, 181, 186, 189
 - agents 180
 - drugs 179, 181
- Anticoagulants 169, 176, 178
- Anticoagulation 79, 106
 - early 106
- Antigenic 132, 179
- Antigenic hypervariability 130
- Antigen isolation 138
- Antigens 43, 44, 129, 133, 134, 135, 136, 138, 140
 - heterologous 134
 - human leukocyte 129
- Antimicrobial properties 139

- APCs 132, 133, 135, 136, 138
 molecules instigating 133
APCs-based vaccines 125
Asparagus racemosus 189
Asthma 96, 111, 112, 185
 and respiratory disorders 111
Autoimmunity 136
- B**
- Brain's parenchyma 108
Broad-spectrum anti-viral agent 33
Bromocriptine 171
Bronchodilation 181, 182
Bronchodilators 185, 187
Bruton's tyrosine kinase (BTK) 180
- C**
- Calcitonin gene-related peptide (CGRP) 176, 178
Cancer 47, 98, 102, 145, 171
 metastatic colon 47
Candidates 48, 126, 130, 131, 134, 137, 141, 142, 146, 148, 154, 158, 159
 modRNA 148
 synthetic 48
 therapeutic 141
Candidate vaccine 135, 139, 140, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155
 advanced 146
 antigens 140
Cardiac 71, 80, 86, 87, 88, 96
 damage 86
 injury 96
 troponin 71, 80, 86, 87, 88
Cardiomyopathy 107
Cardiovascular 83, 87, 96, 100, 106, 107, 182
 adverse events 182
 diseases 83, 87, 96, 100, 106, 107
Case-fatality rate (CFR) 71, 72, 73, 74, 75, 76, 77, 81, 88
Central nervous system complications 108
Cerebral edema 109
Cerebrospinal fluid analysis 109
Cerebrovascular disease 83, 109, 110
Cervical neoplasia 157
Chelating agents 169, 185
Chemokine transcription Suppress 180
Chemoprophylaxis 182
Chicken embryo fibroblasts 134
Chinese 48, 49
 herbal drugs 48
 medicine 49
Cholinesterase inhibitor 178
Chronic 83, 85, 98, 99, 100, 110, 111, 85
 kidney disease (CKD) 83, 85, 98, 99, 100, 110, 111
 obstructive pulmonary disease (COPD) 83, 85, 99, 100, 185
CKD-chronic kidney disease 100
Coagulation disorders 103
Cohort study 87
Computer tomography pulmonary angiogram (CTPA) 79
Coronary 86, 107
 microvascular ischemia 86
 syndrome (CS) 107
Coronavirus disease 27, 28, 71, 72, 74, 75, 76, 88, 96, 98, 125, 131, 169
 novel 71, 72, 88
 pandemic 98
Coronaviruses 9, 15, 97, 111, 129, 141
 novel 111
 pandemic 9
 transmission 15
Corticosteroids 27, 28, 39, 40, 41, 42, 53, 112
 oral 41, 112
 systemic 40
COVID-19 1, 2, 5, 51, 52, 53, 98, 106, 112, 115, 146, 156, 169, 184
 in asthma and rheumatoid arthritis 112
 in cardiovascular diseases 106
 pandemic 51, 52, 53, 98, 146, 156, 169
 reduction of lymphocytes 98
 therapy 115, 184
 transmission 1, 2, 5

Subject Index

COVID-19 disease 46, 169, 171, 172, 173, 175, 176, 177, 178, 179, 180, 181, 182, 184, 185, 186, 187, 188, 189
management of 173, 187
progression of 46, 176, 189
treatment of 171, 172, 179, 180, 181, 182, 184, 186
COVID-19 infection 28, 32, 44, 46, 47, 48, 51, 53, 105, 109, 110, 112, 115
for kidney disease 110
COVID-19 pneumonia 46, 79, 113
severe 46
COVID-19 vaccine 53, 125, 126, 127, 153, 154, 155, 156
development 125, 127, 155
development program 139
Cytokine(s) 42, 45, 47, 51, 77, 78, 85, 86, 88, 97, 101, 105, 109, 115, 127, 128, 138, 176, 177, 179, 180
cascade 109
inflammatory 97, 179
network 176
pro-inflammatory 77, 78, 85, 101, 128
release syndrome 45, 105
secretion 115
signaling 179
production 47
pro-inflammatory 176
Cytokine storm 45, 46, 71, 77, 78, 84, 86, 87, 88, 100, 103, 108, 110, 113
induced 86
inflammatory 84
syndrome 77, 110
Cytomegalovirus 78, 108, 157

D

Damage-associated molecular patterns (DAMPs) 127
Darunavir-cobicistat combination 99
Deep vein thrombosis (DVT) 79
Dehydrogenase, Lactic Acid 173
Dendritic cells (DCs) 125, 132, 135
Diarrhoea 40
Discomfort, gastrointestinal 34

COVID-19: Diagnosis and Management-Part I 203

Diseases 3, 16, 18, 45, 74, 83, 85, 97, 98, 99, 100, 101, 105, 109, 125, 130, 142, 145, 156, 169, 181, 185
alzheimer's 145
asymptomatic 97
autoimmune 181
cardiac 107, 145
chronic inflammatory 101
chronic obstructive pulmonary 83, 85, 185
coronary artery 185
coronavirus-related 71, 75
fearsome 156
mild respiratory 97
rheumatic 45
Disinfection 12, 17
and sanitization of public places 12
of Public Places 12
of surfaces and washrooms 17
Disorders 28, 30, 40, 96, 98, 108, 136
autoimmune 136
chronic medical 98
haematological 30, 40
inflammatory 108
neurologic 96
renal 96
Disseminated intravascular coagulation (DIC) 82, 96, 104, 105, 112
DNA 36, 125, 135, 136, 134, 146, 150, 153, 158
and RNA viruses 36
based vaccines 136, 158
plasmid 135
vaccines 135, 136
Drugs 27, 30, 31, 32, 34, 47, 48, 49, 50, 137, 169, 171, 172, 173, 175, 176, 177, 178, 179, 181, 182, 183, 184, 185, 189
antiarrhythmic 173
antibacterial 184
antidiabetic 173
antifungal 181, 182
antimalarial 181
antipsychotic 176
antirheumatic 173
anti-viral 32, 34
herbal 27, 48, 171

immunosuppressive 185
lysosomotropic 30
Dysfunction 72, 97, 99, 112, 185
 circulatory 99
 cognitive 185
 erectile 185
 multiple organ 72, 97
Dyspnea 71, 82, 96, 111

E

Ebola 35, 151, 152, 156
 vaccine 151, 152, 156
 virus 35
Effects 29, 32, 33, 35, 38, 45, 47, 83, 84, 108,
 176, 177
 antihistaminic 176
 anti-oxidant 83
 anti-viral 33, 35
 immunomodulatory 29, 177
 mild intrinsic antiviral 176
 neurotrophic 108
 renoprotective 84
 synergistic 35, 38, 45
 therapeutic 32, 47
Elastin-like polypeptide (ELPs) 138, 139
Encephalitis 108
Endocrinologists 102
Endocytosis 170, 172, 183
Endothelium-derived relaxing factor (EDRF)
 184
Enzyme 30, 32, 33, 37, 172, 174, 179
 aldehyde oxidase 33
 based assays 179
 inhibiting inosine monophosphate
 dehydrogenase 37
 viral 172
 viral RNA polymerase 174
 RNA polymerases 32
Eosinophils 129
Erythematous rashes 41

G

Gasotransmitters 184
Genome editing techniques 145
Genotoxicity 134, 136
Global vaccine development program (GVDP)
 146
Gut associated lymphoid tissue (GALT) 138

H

Hand(s) 7, 9, 10, 11, 12, 13, 21, 22, 73, 76, 83,
 87, 100, 101, 105
 disinfect 21
 sanitizers 10, 22
 wash 3
Healthcare professionals 1, 10, 46, 116
Health 28, 96
 emergency 28, 96
 machinery 28
 outbreak 28
Heart diseases 83, 100, 102, 107
 concurrent coronary 83
 coronary 83, 100, 107
Heart disorders 102
Hematological complications 103
Hematopoiesis 145
Hemolytic anemia 105, 106
 cold autoimmune 105
Hemostasis systems 103
Hepatitis C virus (HCV) 36, 37, 169
Herpes simplex virus (HSV) 35, 108
Human 99, 133, 187
 immunoglobulin 99
 intestinal organoids 187
 kidney organoids 187
 liver ductal organoids 187
 papilloma virus (HPV) 133
Humoral mediated immunity (HMI) 129, 134,
 157
Hydrocortisone 41
Hyperglycemia 101, 102
Hypertension 71, 83, 98, 100, 101, 107, 185
 pulmonary arterial 185

Subject Index

I

Immune 102, 129, 180
 deficiencies 102
 epitope database and analysis resource 129
 hyperactivation 180
Immune cells 51, 77, 113
 adaptive 51
Immune response 27, 98, 113, 115, 128, 129,
 130, 131, 132, 135, 136, 148, 150, 153,
 154, 155, 176
 all-encompassing 135
 cellular 113, 131
 effective 113
 enhancing 136, 176
 generating 129
 innate 98
 mediated innate 135
 phagocyte-independent 129
Immune system 30, 42, 84, 127, 128, 133,
 134, 170, 172, 179, 185, 187, 189
 adaptive 179
 compromised 170
 dysfunctional 84
Immunity 19, 21, 44, 52, 98, 113, 115, 128,
 129, 130, 134, 138, 153, 157, 159, 189
 cell-mediated 128
 cellular 138
 defensive 115
 elude-pre-established 134
 heterologous 52
 humoral mediated 129
 innate 113
 mucosal 153
 sterilizing 157
Immunization 50, 126, 127, 135, 136, 156,
 157
 passive 157
 technologies 126
 transdermal 136
Immunodeficient mammals 134
Immunogenic epitopes 126, 129
Immunogenicity 131, 132, 134, 136, 141, 155
 mitigated 136
Immunogenic memory 129

COVID-19: Diagnosis and Management-Part I 205

Infection 2, 3, 5, 12, 15, 16, 21, 22, 23, 28, 38,
 39, 44, 51, 78, 79, 85, 96, 97, 103, 107,
 115, 129, 144, 157, 184
 abortive 157
 brain hemorrhage COVID virus 109
 corona 3
 fungal 28, 78, 79
 lymphocyte infiltration lung tissue post 144
 protozoan 39
 secondary 78, 79, 85, 96
 secondary lower respiratory tract 78
 susceptibility 184
 systemic 103
 transfusion-transmitted 51
Inflammation 21, 39, 40, 43, 45, 49, 50, 78,
 108, 109, 175, 176, 177, 178, 179
 pulmonary 78
 reducing lung 176
Influenza vaccines 134, 153, 154
Influenza virus 35, 50, 78, 102, 108, 137
 avian 78
 infection 102
Inhalation 20, 34, 42, 99, 176
 aerosol 34
 anaesthetics 176
 lopinavir-ritonavir-interferon 99
Inhibitors 33, 53, 99, 171, 173, 180, 185, 187
 angiotensin receptor 99
 plasminogen 187
 viral protease 33
Inhibit 30, 172
 post-translational modification 30
 RNA polymerase 172
Injuries 79, 107, 108, 109, 114, 176, 180, 185
 direct endothelial cell 79
 exacerbate ischemia brain 109
 myocardial 107, 108
 parenchymal 176

J

JAK1 prototype cytokine signal 179
JAK2 cytokine signal 179
JAK 179
 inhibitors 179

pathways 179
JAK-STAT 128, 179, 180
pathways 179, 180
signaling pathway 128

K

Kidney 110, 111, 116, 145, 185
disorder 116, 145
dysfunction 185
failure 110
injury 111
Kidney disease 83, 85, 98, 110
chronic 83, 98, 110
underlying chronic 85

L

Lactate dehydrogenase 80, 86
Leishmaniasis 171
Lemon juices 20
Lethal biological agent 3
Leukocytosis 88
Lung disease 83, 185
chronic 83
interstitial 185
Lung infection 40, 42, 43, 113, 176
reduced 42
Lung injury 47, 83
inflammation-related 83
Lung pathology 45, 143
virus-induced macroscopic 45
Lymphocyte(s) 87, 88, 98, 103, 104, 113, 141,
173, 174, 176
activated autoimmune 173, 174
alveolar interstitium 141
apoptosis 88, 103
Lymphocytopenia 47, 104
Lymphopenia 71, 88, 98, 103, 104

M

Macrophage inflammatory protein (MIP) 128
Malignancy 83, 85

Mammalian expression system 133
Masks 1, 2, 3, 4, 5, 6, 12, 14, 15, 16, 17, 18,
22, 23
non-medical 4
triple-layered surgical 1
Massive pulmonary embolism 79
MERS 78, 124, 131, 159
CoV infection 78
epidemics 159
vaccine 134
viruses 131
Metabolic disorder 101
Metalloproteinases 114
Middle east respiratory syndrome (MERS) 32,
53, 71, 75, 78, 131, 141, 143, 171
Mitochondrial enzyme dihydroorotate
dehydrogenase 174
Mitogen-activated protein kinase (MAPK)
185
Monoclonal antibody therapy 43, 45
in COVID-19 treatment 45
Morbidity 100, 111
Morpholino antisense oligonucleotide 145
Mortality 36, 41, 71, 73, 82, 156, 169
colossal 169
pre-reproductive 156
rate 36, 41, 71, 73
reduced 82
Mortality in COVID-19 71, 73, 78, 81, 83, 84,
85, 86, 87, 88
increased risk of 83, 87
Mydriasis 39, 41
Myocardial 86, 87, 107, 108
damage 107, 108
infarction, secondary 87
inflammatory damage 86
Myocarditis 77

N

N-95 Mask 5, 6, 8, 9
gloves 8, 9
Nasal 142, 176
spray 176
turbinates 142

Subject Index

washes 142
Nasogastric tube 47
Nasopharyngeal swab 47
National health commission (NHC) 36, 40, 107
Natural killer (NK) 51, 176, 178
Neurodegenerative disorder 98
Neutralization 45, 127, 129
 assays 127
Neutralizing activity 153
Neutrophilia 88, 112, 113
Next generation sequencing (NGS) 158
Nitazoxanide in COVID-19 Treatment 39
Nitric acid 48
Noninvasive imaging techniques 145
Non-nucleotide reverse transcriptase 174
Nucleoprotein 129
Nucleoside 172, 174
 analog 172
 RNA polymerase 174

O

Oil 20
 coconut 20
 sesame/coconut 20
Open reading frame (ORF) 125
Optimal control thresholds 102
Organ dysfunctioning 47
Oxygenation 52, 178, 184
 extracorporeal membrane 52
Oxygen 82, 108
 saturation 82
 supplementation 82
 supply, reduced 108

P

Pancreatitis 77
Pandemic 12, 27, 76, 158
 dreadful 12
 global 158
 outbreak 27
 wages 76

COVID-19: Diagnosis and Management-Part I 207

Pandemic situations 2, 11, 46, 125
 global 125
Parainfluenza 39
Parkinson's disease 171
Paromomycin 171
Passive immunotherapy 44
Pathogenesis 47, 102, 108, 110, 114, 116, 140, 141, 183
 inflammatory 108
 viral 102, 140, 141
Pathogenicity 130, 132, 157
Pathogens 19, 46, 52, 78, 108, 115, 126, 130, 131, 140, 142, 146
 disease-causative 130
 emerging 46
 infectious 78
Pathway 27, 39, 45, 99, 107, 133, 136, 173, 184
 endocytic 173
 host-regulated 39
 inflammatory 27
 inhibit signal transduction 45
 neuroinflammatory 99
Personal protective equipment (PPEs) 1, 2, 3, 4, 7, 8, 13, 14, 20, 139
Physical 1, 2, 3, 7, 12, 14, 15, 16, 18, 22
 contact 7, 12
 distancing 1, 2, 3, 14, 15, 16, 18, 22
Plasma 33, 35, 50, 51, 52, 100, 185
 convalescent 50, 51, 52
 donating 50
 glucose 100
 protein binding 33
Plasmacytoid 135
Plasma therapy 27, 50, 51
 convalescent 27, 50, 51
Plasminogen 185
Pneumonia 29, 34, 36, 37, 72, 77, 78, 96, 97, 102, 107, 110, 115, 169, 181
 induced 36
 severe 29
 viral 77, 78, 169
Pneumonia COVID-19 113, 185
 progression 185
Polymorphic light eruption (PLE) 28

Polyproteins 174
Population 21, 22, 156
 pediatric 22
 screening 21
 vaccinated 156
Pressure 8, 41, 78, 107, 184
 high blood 41, 107
 increased intrathoracic 78
 pulmonary artery 184
Prevention of COVID-19 transmission 5
Properties 133, 134, 176, 189
 anti-inflammatory 176
 immunomodulatory 189
Protease 27, 30, 32, 33, 49, 137, 172, 174,
 176, 187, 189
 activity 174
 enzyme 27, 33
 lysosomal 187
 serine 176
 viral 32, 137
Protease inhibitors 32, 176
 serine 176
Protein(s) 30, 44, 48, 51, 115, 126, 128, 131,
 132, 133, 138, 140, 141, 170, 181, 182,
 183, 185, 189, 190
 differentiation-associated 128
 fragments 131
 glycosylation patterns 133
 immunological 141
 nucleocapsid 132, 170
 recombinant 126, 131
 ribosomal 115
 synthesized 30
Protein kinase 143, 185
 mitogen-activated 185
Proteolysis 170
Prothrombin time 105
Pulmonary 71, 79, 88, 101, 105, 184, 185
 arterial hypertension (PAH) 185
 downregulation 101
 embolism (PE) 79, 105
 thromboembolism 71, 79, 88
 vasodilators 184
Pulmonary fibrosis 48, 114, 185
 interstitial 48

R

Reactive oxygen species (ROS) 139, 178
Receptor-binding domain (RBD) 44, 45, 131,
 183
Refractory classical hodgkin's lymphoma 47
Release 29, 30, 38, 45, 51, 77, 78, 108, 114,
 133, 139, 170, 179, 180, 183, 187
 cytokine 45, 51, 180
 deregulated 114
 disproportionate 77
 inflammatory cytokines 108
 virion 183
Remdesivir 27, 28, 31, 32, 40, 99, 172, 174,
 189
 therapy 32
 treatment 32
Renin-angiotensin-aldosterone system
 (RAAS) 183, 184
Replication 36, 37, 39, 42, 43, 45, 47, 48, 49,
 134, 135, 137, 141, 142, 144, 170, 172
 enhanced viral 42
 highest viral 142
 inhibiting viral 137
 support SARS 141, 142
Resistance 35, 101
 insulin 101
Respiratory 36, 39, 101, 157
 distress syndrome 101
 syncytial virus (RSV) 36, 39, 157
Respiratory disorders 43, 47, 111, 116
 acute 43, 47
Respiratory syndrome 32, 42, 71, 75, 97, 100,
 114
 acute 42, 114
 severe acute 32, 71, 75, 97, 100
Respiratory syndrome coronavirus 1, 2, 29,
 72, 75, 78, 169
 severe acute 1, 2, 29, 72, 78, 169
Retinoic acid 184
Retinopathy 30
Rhabdomyolysis 96, 110

Subject Index

Rheumatoid arthritis (RA) 28, 45, 96, 98, 112, 115, 116, 181

S

Sanitizer 18

SARS 53, 78, 101, 107, 108, 110, 111, 113, 171, 183
and immunosuppressive effect 53
and middle east respiratory syndrome 171
CoV 78, 101, 107, 108, 110, 111, 113, 183

SARS and MERS 131, 159
epidemics 159
viruses 131

Saskatchewan's vaccine 154

Self-assembling vaccine (SAV) 154

Sequential organ failure assessment (SOFA) 82

Serum 33, 44, 51, 127, 137
albumin 33, 137
immune 44

Serum creatinine 102, 110, 111
base-line 111

Severe acute respiratory syndrome (SARS) 1, 2, 28, 29, 31, 32, 49, 50, 71, 75, 78, 100, 128, 129, 141

Stem cells, mesenchymal 51

Stem cell therapy 51
mesenchymal 51

Surgical Masks 4

Swine flu 137

Symptoms 3, 16, 17, 22, 34, 46, 50, 80, 82, 85, 97, 108, 111, 116, 141, 143, 157

commonest health 97

physiological 157

psychiatric 34

pulmonary 141

respiratory 108

severe 46, 85, 111, 143

Syndrome 28, 45, 100, 107, 109, 157, 171, 176

brain impairment 109

congenital rubella 157

coronary 107

COVID-19: Diagnosis and Management-Part I 209

macrophage activation 45

post-pericardiotomy 171

sjogran's 28

systemic inflammatory 176

System 19, 20, 83, 87, 98, 110, 128, 129, 143, 150, 151, 169, 183, 184

fibrinolytic 87

gastrointestinal 129, 169

hemostatic 84

host defense 98

host-immune 128

human hematopoietic 143

immune function 184

non-viral delivery 150

renal 110

renin-angiotensin-aldosterone 183, 184

Systemic 28, 45, 109

juvenile idiopathic arthritis 45

lupus erythematosus (SLE) 28

toxemia 109

T

Therapy 20, 33, 40, 42, 45, 50, 51, 52, 79, 99, 100, 115, 137

adjuvant 33, 40

antiviral 99

combinational 137

insulin 100

received prophylactic anticoagulant 79

steroid 115

Throat 20, 21, 72, 97

sore 20, 97

swab samples 72

Thromboembolism 71, 80

Thrombopoietin 179

Thrombotic complication, frequent 79

Tinospora cordifolia 189

Tobacco smoking 3, 21

Toxic encephalopathy 109


Transmission 1, 2, 3, 4, 5, 7, 9, 15, 16, 23, 53, 79, 125, 142, 157

airborne 2, 5

chain of 15, 16

droplet 4, 7, 9

- mode of 2, 7
 - mother-to-child 2
 - person-to-person 2
 - Treatment of COVID-19, 33, 34, 37
 - efficacy of ribavirin in 37
 - favipiravir in 33, 34
 - ribavirin in 37
 - Triple-layered medical mask gloves 8
 - Tumor necrosis factor (TNF) 128, 180, 183, 187
- U**
- Ultrasonography 79
- V**
- Vaccination 51, 52, 99, 125, 146, 156
 - post-exposure 99
 - policies 52
 - program 156
 - Vaccine development 125, 126, 130, 146, 156
 - approaches 130
 - programs 126, 146, 153
 - technologies 125
 - Vaccine(s) 1, 27, 52, 53, 126, 130, 131, 132, 133, 134, 135, 138, 140, 141, 142, 148, 150, 151, 152, 153, 154, 156, 157, 158, 189
 - adenovirus-vectored 135
 - attenuated RNA virus 142
 - charitable 157
 - effectiveness 157
 - live attenuated 133
 - monovalent recombinant protein 151
 - mRNA-based 154
 - multi-epitopic peptide 126
 - novel coronavirus 148
 - nucleic acid-based 126
 - oncology 158
 - protein-based 126
 - recombinant 153
 - recombinant-subunit 158
 - replicon RNA 140
 - successful VLP 133
 - technology 126
 - therapeutic 138
 - viral vector-based 134
 - yellow fever 52
 - Vascular endothelial growth factor (VEGF) 43, 47
 - Virus 3, 12, 13, 15, 21, 29, 30, 35, 36, 44, 45, 48, 78, 97, 108, 110, 126, 127, 132, 133, 134, 137, 138, 139, 141, 152, 157, 158
 - herpes simplex 35, 108
 - human papilloma 133
 - inhibit corona 36
 - like particles (VLPs) 126, 132, 133, 138
 - live attenuated 126
 - vaccinia 134
 - varicella-zoster 108
 - variola 78
 - vesicular stomatitis 152
 - zika 29
- W**
- World health organization (WHO) 2, 3, 6, 7, 8, 9, 10, 13, 14, 22, 51, 52, 72, 73, 146



Neeraj Mittal

Dr. Neeraj Mittal works as a scientist B at the Department of Endocrinology, PGIMER, Chandigarh. She completed her M. Pharmacy and PhD (Pharmaceutics) from the Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala. She has worked as a research fellow in DST-funded projects during her doctorate degree. Dr. Neeraj has 7 years of research experience. She has more than 12 publications in national and international journals. Dr. Neeraj has research interests in nanotechnology, bioadhesive drug delivery systems, and other novel drug delivery systems.



Sanjay Kumar Bhadada

Prof. Sanjay Kumar Bhadada (MD, DM (Endocrinology and Metabolism), FICP, FRCPI, and MNAMS) is a professor and the head at the Department of Endocrinology, PGIMER, Chandigarh, which is a premier medical institute of the country, known for its research and patient care worldwide. Currently, he is the National Executive and Ex-Secretary of the Indian Society for Bone and Mineral Research (ISBMR). He is a regular speaker at annual conferences of RSSDI, Endocrine Society of India (ESI), and ISBMR. He has more than 250 publications in highly reputed journals, 14 book chapters, 6 edited books, and 2 patents. He has guided 18 PhD/DM students and 20 MD/MS/MCh students. He has given more than 200 invited talks. Dr. Bhadada has research collaboration with international institutes like Henry Ford Hospital, Detroit, USA and Antwerp University, Belgium, and national institutes. He is the section editor of the ESI Manual of Endocrinology. He has contributed a chapter in the 14th Edition of Williams textbook of Endocrinology. He has received prestigious awards like Prof. Survir Singh Visiting Professorship by Association of Physicians of India, PN Shah and Subash Mukherjee Oration awards by Endocrine Society of India. He also received prestigious M N Sen Oration and Om Prakash Kunti awards by ICMR. He created a social support group for type 1 DM individuals called "ADITI."



Om Prakash Katare

Prof. Om Prakash Katare is currently working as a professor at the University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh. He has published >250 publications, 20 book chapters, 5 edited books, and 19 patents. He has guided 25 PhD students and 50 post-graduate students. He is also working as a reviewer for reputed professional journals. Dr. Katare has an active association with different societies and academies around the world. He has given >150 invited talks. Dr. Katare made his mark in the scientific community with his contributions, gaining wide recognition from honorable subject experts around the world. Dr. Om Prakash Katare has received several awards for the contributions to the scientific community. He has successfully transferred and commercialized 3 novel pharmaceutical products like Psorisome™, Lipotar™ S, and Lipotar™ SS.



Varun Garg

Dr. Varun Garg completed his PhD in Pharmaceutics from the School of Pharmaceutical Sciences, Lovely Professional University. He has published 27 papers in international journals and authored 2 book chapters. He has presented 12 papers at national and international conferences. He has developed himself with a unique profile involving an interplay of research, technical, and medical skills. He has experience of 7 years in medical affairs and has worked with Biocon and Zydus Cadila. Apart from his academic activities, he is actively involved in presenting his research work at different national and international scientific forums.